Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2023-08-03 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is an intimation to stock exchanges regarding a shareholder's request for loss of securities and issuance of duplicate share certificates. It references compliance with SEBI regulations and includes details about the shareholder and share certificates. There are no financial statements, earnings data, or management discussion. The document is a regulatory announcement about share certificate status and procedural updates, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement related to listing obligations and disclosure requirements.
2023-08-03 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the audio recording of an earnings call for the quarter ended June 30, 2023. It references the un-audited financial results and provides a link to the recording. The document is short (1406 characters) and does not contain actual financial data or detailed financial statements, only an announcement about the availability of the earnings call recording. According to the rules, announcements about earnings calls or links to recordings without the full transcript or detailed financial data should be classified as Regulatory Filings (RNS).
2023-08-02 English
Code of Conduct under SEBI(PIT) Reg., 2015
Regulatory Filings Classification · 95% confidence The document is an official communication from Strides Pharma Science Limited to stock exchanges regarding an update to the company's 'Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information' under SEBI (Prohibition of Insider Trading) Regulations, 2015. It includes detailed policy text about insider trading, disclosure practices, and definitions related to unpublished price sensitive information (UPSI). The document is a regulatory compliance disclosure rather than a financial report, earnings release, or management discussion. It does not contain financial statements or results but rather a policy update and procedural information. The document is not a report publication announcement but a regulatory filing informing the exchanges and public about the updated code. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-08-02 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a submission to stock exchanges regarding the Statement of Deviation/Variation in the utilization of funds raised through a preferential issue of equity warrants. It references Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of deviations or variations in use of proceeds from fund raising. The document includes details about the fund raising mode, amount raised, utilization, and confirms no deviation for the quarter ended June 30, 2023. It is a regulatory compliance filing related to fund utilization and not a full financial report, earnings release, or management discussion. It is also not an announcement of a report publication but a direct submission of a compliance statement. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2023-08-02 English
Scheme of Arrangement
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the approval and intimation of a Scheme of Amalgamation under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details the merger of a wholly-owned subsidiary with the parent company, including regulatory references, company details, rationale, and shareholding impact. The document is an announcement of a corporate action (scheme of amalgamation) and not a full report or financial statement. It does not contain comprehensive financial data or detailed financial analysis but rather regulatory disclosures and approvals related to the merger. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as mergers and amalgamations.
2023-08-02 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated August 2, 2023, announcing Strides Pharma Science Limited's consolidated financial results for the quarter Q1FY24. It includes detailed financial highlights such as revenues, EBITDA, gross margins, and segment performance. The document also contains an earnings presentation with detailed financial data, business outlook, and management commentary. The length is about 15,000 characters, indicating a substantive report rather than a brief announcement. The content focuses on quarterly financial results with actual financial statements and analysis, which fits the definition of an Interim / Quarterly Report (IR). It is not merely an earnings release (ER) since it contains detailed financial data and presentation, nor is it a report publication announcement (RPA) or regulatory filing (RNS). Therefore, the appropriate classification is IR with high confidence. Q1 2024
2023-08-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.